|
[1]DONG H,ZHU G,TAMADA K,et al.B7-H1,a third member of the B7 family,co-stimulates T-cell proliferation and interleukin-10 secretion[J].Nat Med,1999,5(12):1365-1369.
|
|
[2]CHEN DS,MELLMAN I.Oncology meets immunology:the cancerimmunity cycle[J].Immunity,2013,39(1):1-10.
|
|
[3]VESELY MD,SCHREIBER RD.Cancer immunoediting:antigens,mechanisms,and implications to cancer immunotherapy[J].Ann N YAcad Sci,2013,1284(1):1-5.
|
|
[4]ZOU W,CHEN L.Inhibitory B7-family molecules in the tumour microenvironment[J].Nat Rev Immunol,2008,8(6):467-477.
|
|
[5]DU LL,HE LL,ZHAO YL,et al.Research advances in immunoregulatory effect of PD-1/PD-LI in Chronic hepatitis B-related primary liver cancer[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition,2014,8(6):860-862.(in Chinese)杜林林,何玲玲,赵亚林,等.PD-1/PD-L1在慢性乙型肝炎相关原发性肝癌中免疫调节作用的研究进展[J/CD].中华实验和临床感染病杂志:电子版,2014,8(6):860-862.
|
|
[6]ZANG X,ALLISON JP.The B7 family and cancer therapy:costimulation and coinhibition[J].Clin Cancer Res,2007,13(18):5271-5279.
|
|
[7]OKAZAKI T,HONJO T.PD-1 and PD-1 ligands:from discovery to clinical application[J].Int Immunol,2007,19(7):813-824.
|
|
[8]HOFMEYER KA,JEON H,ZANG X.The PD-1/PD-L1(B7-H1)pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion[J].J Biomed Biotechnol,2011,2011(6):71-81.
|
|
[9]FIFE BT,PAUKEN KE,EAGAR TN,et al.Interactions between PD-1 and PD-L1 promote tolerance by blocking theT CR-induced stop signal[J].Nat Immunol,2009,10(11):1185-1192.
|
|
[10]PATSOUKIS N,BROWN J,PETKOVA V,et al.Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation[J].Sci Signal,2012,5(230):1755-1762.
|
|
[11]AMARNATH S,MANGUS CW,WANG JC,et al.The PDL1-PD1axis converts human TH1 cells into regulatory T cells[J].Sci Transl Med,2011,3(111):111-120.
|
|
[12]AFREEN S,DERMIME S.The immunoinhibitory B7-H1 molecule as a potential target in cancer:killing many birds with one stone[J].Hematol Oncol Stem Cell Ther,2014,7(1):1-17.
|
|
[13]SHEN MQ,SUN CY,LIU ZJ.Expression and clinical significance of B7-H1 and PD-1 in primary hepatocellular carcinoma tissues[J].World Chin J Dig,2008,16(27):3110-3113.(in Chiese)申民强,孙趁意,刘占举.B7-H1及其受体PD-1分子在原发性肝癌组织中的表达及临床意义[J].世界华人消化杂志,2008,16(27):3110-3113.
|
|
[14]GAO Q,WANG XY,QIU SJ,et al.Overexpression of PD-L1significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma[J].Clin Cancer Res,2009,15(3):971-979.
|
|
[15]WU K,KRYCZEK I,CHEN L,et al.Kupffer cell suppression of CD8+T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions[J].Cancer Res,2009,69(20):8067-8075.
|
|
[16]WANG BJ,BAO JJ,WANG JZ,et al.Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma[J].World J Gastroentero,2011,17(28):3322-3329.
|
|
[17]UMEMOTO Y,OKANO S,MATSUMOTO Y,et al.Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy[J].J Gastroenterol,2014,50(1):1-11.
|
|
[18]KAN G,DONG W.The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology[J].Eur Rev Med Pharmacol Sci,2015,19:3063-3071.
|
|
[19]WU P,WU D,LI L,et al.PD-L1 and survival in solid tumors:a meta-analysis[J].PLoS One,2015,10(6):e0131403.
|
|
[20]PARDOLL DM.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.
|
|
[21]WILKE CM,WEI S,WANG L,et al.Dual biological effects of the cytokines interleukin-10 and interferon-γ[J].Cancer Immunol Immun,2011,60(11):1529-1541.
|
|
[22]CHEN J,LI G,MENG H,et al.Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas[J].Cancer Immunol Immun,2012,61(1):101-108.
|
|
[23]BERTINO G,DEMMA S,ARDIRI A,et al.The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies[J].Biomed Res Int,2015,2015(5):1-12.
|
|
[24]WAHL DR,STENMARK MH,TAO Y,et al.Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma[J].J Clin Oncol,2015,34(5):452-459.
|
|
[25]COUZIN-FRANKEL J.Breakthrough of the year 2013.Cancer immunotherapy[J].Science,2013,342(6165):1432-1433.
|
|
[26]SHI F,SHI M,ZENG Z,et al.PD-1 and PD-L1 upregulation promotes CD8(+)T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients[J].Int J Cancer,2011,128:887-896.
|
|
[27]ZHANG MN.Clinical significance of PD-1 in human hepatocellular carcinoma[D].Beijing:Chinese PLA Postgraduate Medical School,2009.(in Chinese)张敏娜.肝细胞癌患者PD-1表达及其临床意义研究[D].北京:中国人民解放军军医进修学院,2009.
|
|
[28]XIA Y,CHEN R,YE SL,et al.Inhibition of T-cell responses by intratumoral hepatic stellate cells contribute to migration and invasion of hepatocellular carcinoma[J].Clin Exp Metastasis,2011,28(7):661-674.
|
|
[29]SAWADA Y,YOSHIKAWA T,SHIMOMURA M,et al.Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes[J].Int J Oncol,2015,46(1):28-36.
|
DownLoad: